For example, in breast cancer, patients with BAX alteration showed poor prognosis in OS (Overall survival), DSS (Disease-specific survival) and PFS (Progress free survival) (p < 0.05) (Figure 6C). This evidence concerns the gene BAX and breast carcinoma.